Cargando…
Ozone therapy for patients with COVID-19 pneumonia: Preliminary report of a prospective case-control study
BACKGROUND: There is still no specific treatment strategies for COVID-19 other than supportive management. DESIGN: A prospective case-control study determined by admittance to the hospital based on bed availability. PARTICIPANTS: Eighteen patients with COVID-19 infection (laboratory confirmed) sever...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833586/ https://www.ncbi.nlm.nih.gov/pubmed/33310665 http://dx.doi.org/10.1016/j.intimp.2020.107261 |
_version_ | 1783642098336006144 |
---|---|
author | Hernández, Alberto Viñals, Montserrat Pablos, Asunción Vilás, Francisco Papadakos, Peter J Wijeysundera, Duminda N. Bergese, Sergio D. Vives, Marc |
author_facet | Hernández, Alberto Viñals, Montserrat Pablos, Asunción Vilás, Francisco Papadakos, Peter J Wijeysundera, Duminda N. Bergese, Sergio D. Vives, Marc |
author_sort | Hernández, Alberto |
collection | PubMed |
description | BACKGROUND: There is still no specific treatment strategies for COVID-19 other than supportive management. DESIGN: A prospective case-control study determined by admittance to the hospital based on bed availability. PARTICIPANTS: Eighteen patients with COVID-19 infection (laboratory confirmed) severe pneumonia admitted to hospital between 20th March and 19th April 2020. Patients admitted to the hospital during the study period were assigned to different beds based on bed availability. Depending on the bed the patient was admitted, the treatment was ozone autohemotherapy or standard treatment. Patients in the case group received ozonated blood twice daily starting on the day of admission for a median of four days. Each treatment involved administration of 200 mL autologous whole blood enriched with 200 mL of oxygen-ozone mixture with a 40 μg/mL ozone concentration. MAIN OUTCOMES: The primary outcome was time from hospital admission to clinical improvement. RESULTS: Nine patients (50%) received ozonated autohemotherapy beginning on the day of admission. Ozonated autohemotherapy was associated with shorter time to clinical improvement (median [IQR]), 7 days [6–10] vs 28 days [8–31], p = 0.04) and better outcomes at 14-days (88.8% vs 33.3%, p = 0.01). In risk-adjusted analyses, ozonated autohemotherapy was associated with a shorter mean time to clinical improvement (−11.3 days, p = 0.04, 95% CI –22.25 to −0.42). CONCLUSION: Ozonated autohemotherapy was associated with a significantly shorter time to clinical improvement in this prospective case-control study. Given the small sample size and study design, these results require evaluation in larger randomized controlled trials. Clinical trial registration number: NCT04444531. |
format | Online Article Text |
id | pubmed-7833586 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Authors. Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78335862021-01-26 Ozone therapy for patients with COVID-19 pneumonia: Preliminary report of a prospective case-control study Hernández, Alberto Viñals, Montserrat Pablos, Asunción Vilás, Francisco Papadakos, Peter J Wijeysundera, Duminda N. Bergese, Sergio D. Vives, Marc Int Immunopharmacol Preliminary Report BACKGROUND: There is still no specific treatment strategies for COVID-19 other than supportive management. DESIGN: A prospective case-control study determined by admittance to the hospital based on bed availability. PARTICIPANTS: Eighteen patients with COVID-19 infection (laboratory confirmed) severe pneumonia admitted to hospital between 20th March and 19th April 2020. Patients admitted to the hospital during the study period were assigned to different beds based on bed availability. Depending on the bed the patient was admitted, the treatment was ozone autohemotherapy or standard treatment. Patients in the case group received ozonated blood twice daily starting on the day of admission for a median of four days. Each treatment involved administration of 200 mL autologous whole blood enriched with 200 mL of oxygen-ozone mixture with a 40 μg/mL ozone concentration. MAIN OUTCOMES: The primary outcome was time from hospital admission to clinical improvement. RESULTS: Nine patients (50%) received ozonated autohemotherapy beginning on the day of admission. Ozonated autohemotherapy was associated with shorter time to clinical improvement (median [IQR]), 7 days [6–10] vs 28 days [8–31], p = 0.04) and better outcomes at 14-days (88.8% vs 33.3%, p = 0.01). In risk-adjusted analyses, ozonated autohemotherapy was associated with a shorter mean time to clinical improvement (−11.3 days, p = 0.04, 95% CI –22.25 to −0.42). CONCLUSION: Ozonated autohemotherapy was associated with a significantly shorter time to clinical improvement in this prospective case-control study. Given the small sample size and study design, these results require evaluation in larger randomized controlled trials. Clinical trial registration number: NCT04444531. The Authors. Published by Elsevier B.V. 2021-01 2020-12-05 /pmc/articles/PMC7833586/ /pubmed/33310665 http://dx.doi.org/10.1016/j.intimp.2020.107261 Text en © 2020 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Preliminary Report Hernández, Alberto Viñals, Montserrat Pablos, Asunción Vilás, Francisco Papadakos, Peter J Wijeysundera, Duminda N. Bergese, Sergio D. Vives, Marc Ozone therapy for patients with COVID-19 pneumonia: Preliminary report of a prospective case-control study |
title | Ozone therapy for patients with COVID-19 pneumonia: Preliminary report of a prospective case-control study |
title_full | Ozone therapy for patients with COVID-19 pneumonia: Preliminary report of a prospective case-control study |
title_fullStr | Ozone therapy for patients with COVID-19 pneumonia: Preliminary report of a prospective case-control study |
title_full_unstemmed | Ozone therapy for patients with COVID-19 pneumonia: Preliminary report of a prospective case-control study |
title_short | Ozone therapy for patients with COVID-19 pneumonia: Preliminary report of a prospective case-control study |
title_sort | ozone therapy for patients with covid-19 pneumonia: preliminary report of a prospective case-control study |
topic | Preliminary Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833586/ https://www.ncbi.nlm.nih.gov/pubmed/33310665 http://dx.doi.org/10.1016/j.intimp.2020.107261 |
work_keys_str_mv | AT hernandezalberto ozonetherapyforpatientswithcovid19pneumoniapreliminaryreportofaprospectivecasecontrolstudy AT vinalsmontserrat ozonetherapyforpatientswithcovid19pneumoniapreliminaryreportofaprospectivecasecontrolstudy AT pablosasuncion ozonetherapyforpatientswithcovid19pneumoniapreliminaryreportofaprospectivecasecontrolstudy AT vilasfrancisco ozonetherapyforpatientswithcovid19pneumoniapreliminaryreportofaprospectivecasecontrolstudy AT papadakospeterj ozonetherapyforpatientswithcovid19pneumoniapreliminaryreportofaprospectivecasecontrolstudy AT wijeysunderadumindan ozonetherapyforpatientswithcovid19pneumoniapreliminaryreportofaprospectivecasecontrolstudy AT bergesesergiod ozonetherapyforpatientswithcovid19pneumoniapreliminaryreportofaprospectivecasecontrolstudy AT vivesmarc ozonetherapyforpatientswithcovid19pneumoniapreliminaryreportofaprospectivecasecontrolstudy |